Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
about
P1343
Crizotinib resistance: implications for therapeutic strategiesThe role of the ALK receptor in cancer biologyCrizotinib: from discovery to accelerated development to front-line treatmentTackling ALK in non-small cell lung cancer: the role of novel inhibitorsNew treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinibMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsOncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsPersonalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for CeritinibTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyCIViC databaseStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerFocus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practicePerfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsBiomarkers and targeted systemic therapies in advanced non-small cell lung cancerAlectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.Clinical Challenges to Current Molecularly Targeted Therapies in Lung CancerComprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Second-generation anaplastic lymphoma kinase inhibitors: revolutionary or evolutionary?The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNALK: a tyrosine kinase target for cancer therapy.First-line treatment of advanced ALK-positive non-small-cell lung cancer.Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Detecting and targetting oncogenic fusion proteins in the genomic era.Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.
P2860
073efbc6b1d1b3b7b88de9854f924dcf2323523857c0c6fb63a8633c5029e43f7cbe69aa10efc5a89b6530aad9a2946a10c55ec1a4403c5dbcb9f267b3e7cbec2949467595a9b22cd700e0c4995efa9fb97e8bc2831d0c61bb8f739ad0fb263b5bd27a2de1370ea20606dddfb05499f5607ac54fd5f53869e1e25c075febfd5c90873fa1f802fcddd31de006f89b2efb6a33257873592c8f242f35bd18bf5010fe630449eb374d8317baa1ef5773d0a71bf99751
P248
Q26738381-E7E1162E-B5E5-4593-A6BD-CCDFE16580E5Q26738384-60901D1F-A7CD-4553-A05E-4F9C1E164CB1Q26738385-0075531E-A654-431F-9470-81CD48C9C7FDQ26740329-163ABBB1-2971-4D33-B0E3-D339F476AD7CQ26746230-CD252141-DF64-46E3-ABB0-C1091C32E7D5Q26769659-76C21454-9D96-45A9-BF94-B8DB12A1CAE5Q26774625-9BAAB611-A5DD-4C61-86D6-CAD1481A56EBQ26775817-5A3F30F4-BC65-4B15-A1E2-6BBA9E1D7B18Q26795555-18549662-3F00-43DA-846B-CDC529A0369BQ27612411-E7E6D6A0-CAF5-4CAA-8D2E-FBE1DFEB7248Q27853214-7B6A82C5-1E76-4800-A648-24D359BC828DQ28067196-F38AC94D-4290-48CE-B17F-29E893202DAEQ28068643-D8B5DA7F-7232-4D24-8596-6458D9964BB8Q28071903-59616A35-764A-4BCD-8906-2B258CA769BFQ35461464-745ABAF9-5847-4C94-9ADB-F74F965D53F6Q35743004-AC63BB4F-4B42-4522-AD69-8F39EC4E27B4Q35858617-CBB94992-D615-402B-A5AD-68B1A60AA3B7Q36260477-17741372-1062-4A84-9194-56EE40B8884CQ36550838-C5E558AB-32DE-43E6-90BD-EC7633347F28Q36972377-39F2369C-4E9D-4868-A1B4-BB3DA2C09BE8Q37017060-37136EB5-F87F-4190-A6BE-F8AE318F21BFQ37121477-EF9CA5B3-F834-4923-A34E-A436290D9E59Q37305906-D54B6D2F-1DC9-4775-ABF5-4F2C5B6E9487Q37518624-D2C1CDBF-180E-44A6-B550-E4A5972178C3Q37566842-C69FFA44-7D96-455B-B4E5-D9942EF89B7AQ37592115-0751828B-5565-4349-805B-1EACB6CAD9B9Q37666880-D4CEBDB7-D0D5-48D4-A94B-8B0C2D72C02EQ37709234-0353B0E5-B3B0-4E5D-B09E-6BE6A31D5206Q38336067-AFA9D0FC-6690-43BA-BFCB-B397367A58A1Q38355156-A2FCDE52-95B5-461E-83CD-413E9B4F5DE9Q38459398-81D3F097-94B3-4E0B-ADAD-91809D08BB8EQ38484053-0FC359EC-BD02-4EF0-A244-FA1FF73946F6Q38558178-1090EB72-F5C7-4960-A655-723682BCBD66Q38576015-0B324016-4836-4926-8864-D8A4818F5984Q38584814-6B7841C9-FE87-48E9-9703-1D30D9CF1CBBQ38631019-0666BC6F-5645-4CFD-9E79-15CF2F62D7F0Q38663460-145FCC18-FC16-4761-962F-26D9B5321972Q38736644-A2DFA057-2E54-4B80-A507-9AEA1D0BC0C7Q38737681-E9D9D82E-6784-499C-BBA0-B3867F94B040Q38739807-5E5DF0CB-4FD2-48B1-A3FF-2B97F07DDC27
P2860
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Two novel ALK mutations mediat ...... ration ALK inhibitor alectinib
@ast
Two novel ALK mutations mediat ...... ration ALK inhibitor alectinib
@en
Two novel ALK mutations mediat ...... ation ALK inhibitor alectinib.
@nl
type
label
Two novel ALK mutations mediat ...... ration ALK inhibitor alectinib
@ast
Two novel ALK mutations mediat ...... ration ALK inhibitor alectinib
@en
Two novel ALK mutations mediat ...... ation ALK inhibitor alectinib.
@nl
altLabel
Two Novel ALK Mutations Mediat ...... ration ALK Inhibitor Alectinib
@en
prefLabel
Two novel ALK mutations mediat ...... ration ALK inhibitor alectinib
@ast
Two novel ALK mutations mediat ...... ration ALK inhibitor alectinib
@en
Two novel ALK mutations mediat ...... ation ALK inhibitor alectinib.
@nl
P2093
P2860
P50
P3181
P1476
Two novel ALK mutations mediat ...... ration ALK inhibitor alectinib
@en
P2093
A John Iafrate
Alice T Shaw
Elizabeth L Lockerman
Jeffrey A Engelman
Justin F Gainor
Makoto Taiji
Naoya Fujita
Sumie Koike
Tahsin M Khan
Yasushi Okuno
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-14-1511
P407
P4510
P577
2014-11-15T00:00:00Z